Children are more susceptible to developing allergic asthma than adults. An estimated 6 million children have allergic asthma, making asthma one of the most common long-term diseases of childhood. Asthma is potentially life-threatening, yet there is no cure, rather only management of symptoms. Progress in understanding the disease was reported in the Dec 17, 2019, issue of Immunity.
Seongnam, Korea-based Bridge Biotherapeutics Inc. nailed down a deal with Boehringer Ingelheim GmbH (BI) to develop the former's phase I autotaxin (ATX) inhibitor, BBT-877, for fibrosing interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF).